Treatment of the Diabetic Heart Failure Patient
Published: 01 July 2020
-
Views:
339
-
Likes:
2
Overview
Full programme
-
Views:
339
-
Likes:
2
Overview
Prof Mark Petrie (University of Glasgow, Glasgow, UK) joins Dr Mikhail N Kosiborod (Saint Luke's Mid America Heart Institute, Kansas City, US) to discuss heart failure in patients with diabetes with consideration to new data emerging from SGLT2 inhibitors and GLP-1 Receptor Agonists.

Series overview
Part 1
Diabetes and Heart Failure Outcomes
1 session | |
Diabetes and Heart Failure Outcomes | Watch now |
Part 2
SGLT2 Inhibitors in Heart Failure
1 session | |
SGLT2 Inhibitors in Heart Failure | Watch now |
Part 3
GLP-1 Receptor Agonists in Heart Failure
Faculty Biographies

Mikhail Kosiborod
Cardiologist
Dr Mikhail Kosiborod is a cardiologist who serves as Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.
He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

Mark Petrie
Professor/Honorary Consultant (Institute of Cardiovascular & Medical Sciences)
Professor Mark Petrie worked as an interventional cardiologist before his professorship at University of Glasgow. His interests include revascularization in heart failure, diabetes and cardiovascular disease and cardio-oncology.